研究者業績

谷口 俊文

タニグチ トシブミ  (Toshibumi Taniguchi)

基本情報

所属
千葉大学 医学部附属病院 感染症内科・感染制御部 准教授
学位
医学博士(2013年9月 千葉大学)

研究者番号
20724826
ORCID ID
 https://orcid.org/0000-0002-7732-9870
J-GLOBAL ID
201801008269119836
Researcher ID
O-8445-2017
researchmap会員ID
B000289285

千葉大学医学部を2001年に卒業、武蔵野赤十字病院での初期研修、在沖米国海軍病院のインターンを経て、2005年よりSt. Luke's-Roosevelt Hospital Centerの内科レジデント、その後2008年よりWashington University in St. Louisの感染症科フェローを修了。その後は日本に帰国して学位取得後、2014年より千葉大学医学部附属病院感染制御部・感染症内科に在籍。米国内科専門医、米国感染症専門医、日本内科学会総合内科専門医、日本感染症学会感染症専門医・指導医。

専門は感染症、その中でもHIVの治療と予防、啓発活動。またCOVID-19の治療(日本感染症学会のCOVID-19治療薬タスクフォースのメンバー)、ワクチンの啓発活動(こびナビの幹事)に従事。日本のSARS-CoV-2ワクチン接種率向上に寄与した。こびナビの活動は厚生労働省「第三回上手な医療のかかり方アワード」にて厚生労働大臣・最優秀賞を受賞。

現在はHIVの予防(PrEP: Pre-Exposure Prophylaxis)と早期治療(Rapid ART)の研究と推進、COVID-19治療の平準化の推進、抗菌薬適正使用による薬剤耐性菌(AMR)対策の推進などを行っている。

現在はX(旧Twitter)で感染症全般の啓発活動を続け、YouTubeにて一般向けの感染症情報の発信を行っている。

 

 


学歴

 2

論文

 84
  • Yuriko Yamazaki, Tomoka Ito, Seitaro Nakagawa, Takashi Sugihira, Chinami Kurita-Tachibana, Amer E. Villaruz, Kensuke Ishiguro, Barbora Salcman, Shuo Li, Sanami Takada, Naohiro Inohara, Yoko Kusuya, Aki Shibata, Masakazu Tamai, Reika Aoyama, Kanako Inoue, Shota Murata, Kazuyuki Matsushita, Akiko Miyabe, Toshibumi Taniguchi, Hidetoshi Igari, Naruhiko Ishiwada, Masateru Taniguchi, Taka-Aki Nakada, Hiroyuki Matsue, Manabu Fujimoto, Haruka Hishiki, Yoshiteru Osone, Hiromichi Hamada, Naoki Shimojo, Tsutomu Suzuki, Michael Otto, Gabriel Núñez, Hiroki Takahashi, Akiko Takaya, Yuumi Nakamura
    Nature Communications 15(1) 2024年11月7日  
  • Kazuto Aono, Yoshiro Maezawa, Hisaya Kato, Hiyori Kaneko, Yoshitaka Kubota, Toshibumi Taniguchi, Toshiyuki Oshitari, Sei‐Ichiro Motegi, Hironori Nakagami, Akira Taniguchi, Kazuhisa Watanabe, Minoru Takemoto, Masaya Koshizaka, Koutaro Yokote
    Geriatrics & Gerontology International 2024年8月24日  
  • Hidetoshi Igari, Seiichiro Sakao, Takayuki Ishige, Kengo Saito, Shota Murata, Misuzu Yahaba, Toshibumi Taniguchi, Akiko Suganami, Kazuyuki Matsushita, Yutaka Tamura, Takuji Suzuki, Eiji Ido
    Nature Communications 15(1) 2024年4月29日  
    Abstract Numerous SARS-CoV-2 variant strains with altered characteristics have emerged since the onset of the COVID-19 pandemic. Remdesivir (RDV), a ribonucleotide analogue inhibitor of viral RNA polymerase, has become a valuable therapeutic agent. However, immunosuppressed hosts may respond inadequately to RDV and develop chronic persistent infections. A patient with respiratory failure caused by interstitial pneumonia, who had undergone transplantation of the left lung, developed COVID-19 caused by Omicron BA.5 strain with persistent chronic viral shedding, showing viral fusogenicity. Genome-wide sequencing analyses revealed the occurrence of several viral mutations after RDV treatment, followed by dynamic changes in the viral populations. The C799F mutation in nsp12 was found to play a pivotal role in conferring RDV resistance, preventing RDV-triphosphate from entering the active site of RNA-dependent RNA polymerase. The occurrence of diverse mutations is a characteristic of SARS-CoV-2, which mutates frequently. Herein, we describe the clinical case of an immunosuppressed host in whom inadequate treatment resulted in highly diverse SARS-CoV-2 mutations that threatened the patient’s health due to the development of drug-resistant variants.
  • 戸来 依子, 横田 翔, 吉川 寛, 矢幅 美鈴, 谷口 俊文, 村田 正太, 千葉 均, 猪狩 英俊
    日本呼吸器学会誌 13(増刊) 278-278 2024年3月  
  • Yui Sakai, Toshibumi Taniguchi, Yoriko Herai, Misuzu Yahaba, Akira Watanabe, Katsuhiko Kamei, Hidetoshi Igari
    Cureus 16(2) e53550 2024年2月  
    We report the case of an 84-year-old man with a history of IgG4-related sclerosing cholangitis who was diagnosed with advanced esophageal cancer and underwent radiation and chemotherapy. An implantable central venous access port was placed for chemotherapy and total parenteral nutrition. The patient presented with a fever and received antimicrobial therapy for acute cholangitis but remained febrile, and subsequently, yeast was detected in the aerobic bottle of blood culture obtained from the central venous line. The yeast was identified as Wickerhamomyces anomalus. Liposomal amphotericin B was administered, and the central line access port was removed. After confirmation of negative blood cultures and 14 days post treatment, he underwent reinsertion of the central line access port. Due to persistent pain at the insertion site, fluconazole was added for an additional 14 days, and the patient was discharged and transferred to another hospital. Wickerhamomyces anomalus is a rare fungal infection with other synonyms including Pichia anomala, Hansenula anomala, and Candida pelliculosa. A literature review of 53 case reports of Wickerhamomyces anomalus, Pichia anomala, Hansenula anomala, and Candida pelliculosa was conducted, with a total of 211 cases reviewed. Fungemia was reported in 94% of cases, with central venous catheterization, parental feeding, low birth weight, and immunocompromised status identified as major risk factors. The majority of cases were pediatric, particularly neonatal, and there were reports of nosocomial infections causing outbreaks, with some cases involving the eye such as endophthalmitis or keratitis.

MISC

 153

書籍等出版物

 29

講演・口頭発表等

 52

担当経験のある科目(授業)

 2

主要な共同研究・競争的資金等の研究課題

 19

社会貢献活動

 38

メディア報道

 41